文献速递胸部肿瘤放疗放疗物理与技术

气管原发腺样囊性癌:单中心38例跨学科治疗临床结局

Primary adenoid cystic carcinoma of the trachea: clinical outcome of 38 patients after interdisciplinary treatment in a single institution.
PubMed 文献 · Radiat Oncol · 2019-07-04

回顾性分析1991至2017年海德堡大学医院38例气管腺样囊性癌患者,接受手术和/或放疗(碳离子或光子)。全组5年总生存95%,5年局部无进展生存96%,5年远处无进展生存69%。手术患者预后良好,术后辅助放疗可获良好总生存,碳离子放疗初步结果有前景但需更多数据。

要点

  • 气管腺样囊性癌罕见,手术是长期预后良好的关键。
  • 全组5年OS 95%、FFLP 96%、FFDP 69%。
  • 碳离子放疗初步结果有前景,但需更多数据验证长期优势。

核心结论

  • 手术切除可获良好长期预后,不完全切除后辅助放疗仍可取得良好总生存。
  • 碳离子放疗初步结果有前景,但需更多数据证明其较光子的长期优势。

研究设计与样本

  • 单中心回顾性分析1991至2017年海德堡大学医院38例组织学确诊气管腺样囊性癌患者。
  • 患者接受手术和/或放疗(碳离子7例或光子24例),前瞻性采集资料并回顾性分析。
  • 38例中女性23例、男性15例,中位年龄51岁,中位随访74.5个月。

主要发现

  • 全组5年OS 95%(10年81%),5年FFLP 96%(10年83%),5年FFDP 69%(10年53%)。
  • 单纯手术患者5年OS 100%(10年80%),5年FFLP 100%(10年100%),5年FFDP 80%(10年60%)。
  • 单纯放疗患者5年OS 100%(10年83%),5年FFLP 88%(10年44%),5年FFDP 67%(10年34%)。
  • 手术加辅助放疗患者5年OS 84%(10年84%),5年FFLP 100%(10年100%),5年FFDP 65%(10年65%)。

关键数值与推荐

  • 61%患者为局部晚期(4期)腺样囊性癌。
  • 不可切除、严重合并症或手术切除不完整者,目前推荐根治性放疗。

临床怎么用

  • 可手术患者应优先考虑手术以获得良好长期预后。
  • 不完全切除后行辅助放疗仍可取得良好总生存。
  • 碳离子放疗可作为有前景的选择,但需更多数据支持其长期优势。

局限性

  • 回顾性单中心分析,样本量38例。
  • 碳离子放疗仅7例,数据有限,需更多数据证明其长期优势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary adenoid cystic carcinomas (ACCs) of the trachea are rare tumors of the central bronchial system. In patients presenting with unresectable tumors, severe comorbidities, or incomplete surgical resection, definitive radiotherapy is currently the recommended treatment. Irradiation with carbon ions (C12) has shown promising local control (LC) and survival rates in cases of ACCs of the head and neck. No data on the therapeutic efficacy of C12 radiotherapy in treating tracheal ACC has been published. METHODS: All patients with histologically confirmed ACC of the trachea treated with surgery and/or radiation treatment at Heidelberg University Hospital between 1991 and 2017 were included in this analysis. Patient and treatment characteristics, short- and long-term toxicity after radiotherapy, overall survival (OS), freedom from local progression (FFLP), and freedom from distant progression (FFDP) were prospectively acquired and retrospectively analyzed. RESULTS: Thirty-eight patients (23 women and 15 men) with a median age of 51 were treated by surgery (n = 20) and/or radiotherapy with either C12 (n = 7) or photons (n = 24). Of these patients, 61% presented with locally advanced (stage 4) ACC. The median follow-up for all patients was 74.5 months. The 5-year OS for all patients was 95% (10-year: 81%). The 5-year FFLP and FFDP were 96% (10-year: 83%) and 69% (10-year: 53%), respectively. In patients who underwent surgery alone, the 5-year OS was 100% (10-year: 80%). The 5-year FFLP and FFDP were 100% (10-year: 100%) and 80% (10-year: 60%), respectively. In patients who underwent radiotherapy alone, the 5-year OS was 100% (10-year: 83%). The 5-year FFLP and FFDP were 88% (10-year: 44%) and 67% (10-year: 34%), respectively. In patients who received multi-modal treatment including surgery and adjuvant radiotherapy, the 5-year OS was 84% (10-year: 84%). The 5-year FFLP was 100% (10-year: 100%) and the 5-year FFDP was 65% (10-year, 65%). CONCLUSIONS: The long-term prognosis is favorable if surgery is performed. In cases of an incomplete resection, good OS can still be achieved following adjuvant radiotherapy. For radiotherapy, irradiation with C12 shows promising first results. However, more data is needed to prove the long-term advantage of C12 over photons. TRIAL REGISTRATION: The ethics committee of the Heidelberg University Hospital approved the retrospective data analysis (S-174/2019).

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Högerle BA, Lasitschka F, Muley T, et al. Primary adenoid cystic carcinoma of the trachea: clinical outcome of 38 patients after interdisciplinary treatment in a single institution. Radiat Oncol. 2019. PMID: 31272473. doi:10.1186/s13014-019-1323-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。